JPMorgan Chase & Co. Lowers Insulet (NASDAQ:PODD) Price Target to $275.00

Insulet (NASDAQ:PODD) had its price objective dropped by investment analysts at JPMorgan Chase & Co. from $340.00 to $275.00 in a research report issued to clients and investors on Thursday, Marketbeat.com reports. The firm currently has an “overweight” rating on the medical instruments supplier’s stock. JPMorgan Chase & Co.‘s target price would suggest a potential upside of 78.39% from the company’s current price.

PODD has been the topic of several other reports. Weiss Ratings upgraded Insulet from a “hold (c-)” rating to a “hold (c)” rating in a report on Friday, May 1st. Canaccord Genuity Group reduced their target price on Insulet from $450.00 to $435.00 and set a “buy” rating on the stock in a report on Wednesday, February 18th. Truist Financial reduced their target price on Insulet from $360.00 to $315.00 and set a “buy” rating on the stock in a report on Wednesday, April 15th. Raymond James Financial reduced their target price on Insulet from $385.00 to $355.00 and set an “outperform” rating on the stock in a report on Thursday, February 19th. Finally, TD Cowen lowered Insulet from a “buy” rating to a “hold” rating and set a $294.00 target price on the stock. in a report on Monday, January 26th. Eighteen analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Insulet currently has an average rating of “Moderate Buy” and a consensus price target of $257.09.

Insulet Stock Down 3.9%

NASDAQ:PODD opened at $154.16 on Thursday. Insulet has a 12-month low of $148.30 and a 12-month high of $354.88. The company has a quick ratio of 2.15, a current ratio of 2.49 and a debt-to-equity ratio of 0.71. The firm has a market capitalization of $10.68 billion, a P/E ratio of 35.85, a P/E/G ratio of 0.92 and a beta of 1.20. The stock’s fifty day simple moving average is $211.22 and its 200-day simple moving average is $263.85.

Insulet (NASDAQ:PODD) last posted its quarterly earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.19 by $0.23. The business had revenue of $761.70 million for the quarter, compared to analyst estimates of $729.89 million. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The firm’s revenue was up 33.9% on a year-over-year basis. During the same period last year, the company earned $1.02 EPS. Insulet has set its FY 2026 guidance at 6.210- EPS. Equities research analysts expect that Insulet will post 6.46 earnings per share for the current year.

Insider Activity at Insulet

In other news, Director Michael R. Minogue purchased 2,030 shares of the business’s stock in a transaction dated Wednesday, February 25th. The shares were bought at an average cost of $246.23 per share, for a total transaction of $499,846.90. Following the completion of the acquisition, the director directly owned 17,483 shares in the company, valued at approximately $4,304,839.09. This trade represents a 13.14% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.36% of the stock is currently owned by company insiders.

Institutional Trading of Insulet

A number of institutional investors have recently modified their holdings of PODD. NewEdge Advisors LLC lifted its holdings in shares of Insulet by 44.8% in the first quarter. NewEdge Advisors LLC now owns 207 shares of the medical instruments supplier’s stock valued at $54,000 after purchasing an additional 64 shares in the last quarter. Cresset Asset Management LLC lifted its holdings in shares of Insulet by 7.3% in the second quarter. Cresset Asset Management LLC now owns 2,587 shares of the medical instruments supplier’s stock valued at $813,000 after purchasing an additional 177 shares in the last quarter. Cerity Partners LLC lifted its holdings in shares of Insulet by 68.7% in the second quarter. Cerity Partners LLC now owns 17,262 shares of the medical instruments supplier’s stock valued at $5,423,000 after purchasing an additional 7,030 shares in the last quarter. Sei Investments Co. increased its position in shares of Insulet by 27.4% in the second quarter. Sei Investments Co. now owns 137,643 shares of the medical instruments supplier’s stock valued at $43,245,000 after acquiring an additional 29,584 shares during the last quarter. Finally, Treasurer of the State of North Carolina increased its position in shares of Insulet by 2.5% in the second quarter. Treasurer of the State of North Carolina now owns 32,752 shares of the medical instruments supplier’s stock valued at $10,290,000 after acquiring an additional 791 shares during the last quarter.

More Insulet News

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Insulet’s Q1 results beat expectations, with revenue of $761.7 million and EPS of $1.42, and management raised full-year revenue growth guidance to 21%–23%, reinforcing momentum in its Omnipod diabetes platform.
• Positive Sentiment: The company highlighted strong international Omnipod growth and continued expansion of Omnipod 5 into new markets, which suggests the core business remains healthy. Article Title
• Neutral Sentiment: Recent earnings-call coverage and transcript coverage continued to emphasize improved profitability and upbeat management commentary following the Q1 report. Article Title
• Negative Sentiment: Multiple Wall Street firms cut price targets sharply after the earnings report, including Piper Sandler, JPMorgan, Citigroup, Wells Fargo, Stifel, Raymond James, Canaccord Genuity, Leerink, and others, which likely pressured the shares.
• Negative Sentiment: The stock is also trading well below several recent analyst targets, and the cluster of downgrades/target reductions may be signaling concerns about valuation or the pace of future upside despite the earnings beat.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.